The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Roberto Iacovelli
Honoraria - Astellas Pharma; IPSEN; MSD; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Eisai; Genenta Science; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi
Speakers' Bureau - Ipsen; Janssen; MSD; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen; MSD; Pfizer
 
Chiara Ciccarese
Honoraria - Astellas Oncology; AstraZeneca; Eisai; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis
Travel, Accommodations, Expenses - Astellas Oncology; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck Sharp & Dohme; Pfizer
 
Sebastiano Buti
Consulting or Advisory Role - Astellas Pharma; BMS; GENTILI; Ipsen; Merck; Merck/Pfizer; MSD; Pfizer
Speakers' Bureau - Astellas Pharma; BMS; Ipsen; Merck; Merck/Pfizer; MSD; Pfizer
Research Funding - GENTILI; Novartis (Inst); Pfizer (Inst)
 
Paolo Andrea Zucali
Honoraria - Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Astellas Oncology; AstraZeneca; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer
 
Marco Maruzzo
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Janssen; Merck Serono; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Ipsen; Janssen
 
Elena Verzoni
Honoraria - Eisai; Ipsen; Janssen; MSD Oncology; Novartis
Consulting or Advisory Role - Janssen Oncology; MSD/AstraZeneca; Pfizer
 
Caterina Accettura
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Lucia Bonomi
Research Funding - Regeneron; Roche
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology
 
Consuelo Buttigliero
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Giuseppe Fornarini
No Relationships to Disclose
 
Stefania Pipitone
Travel, Accommodations, Expenses - Pfizer
 
Cristina Masini
Consulting or Advisory Role - Astellas Pharma; Ipsen; Janssen; MSD
Travel, Accommodations, Expenses - Ipsen
 
Francesco Massari
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Medivation; AstraZeneca; Bayer; BMS; Ipsen; Janssen Oncology; Merck; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Janssen Oncology
 
Francesca Primi
Travel, Accommodations, Expenses - Astellas Oncology
 
Emanuela Fantinel
Travel, Accommodations, Expenses - Ipsen
 
Daniela Arduini
Travel, Accommodations, Expenses - Novartis Italy
 
Diana Giannarelli
No Relationships to Disclose
 
Robert Motzer
Consulting or Advisory Role - Merck
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst); Pfizer (Inst)
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Caris Life Sciences; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
(OPTIONAL) Uncompensated Relationships - AACR Scientific Advisory Council